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Background: A species of the fungal genus Cordyceps has been used as a complementary and alternative medicine
of traditional Chinese medicine, and its major component cordycepin and cordycepin-enriched WIB-801CE are
known to have antiplatelet effects in vitro. However, it is unknown whether they have also endogenous antiplatelet
and antithrombotic effects. In this study, to resolve these doubts, we prepared cordycepin-enriched WIB-801CE, an
ethanol extract from Cordyceps militaris-hypha, then evaluated its ex vivo, in vivo, and in vitro antiplatelet and
antithrombotic effects.
Methods: Ex vivo effects of WIB-801CE on collagen- and ADP-induced platelet aggregation, serotonin release,
thromboxane A2 (TXA2) production and its associated activities of enzymes [cyclooxygenase-1 (COX-1), TXA2
synthase (TXAS)], arachidonic acid (AA) release and its associated phosphorylation of phospholipase Cβ3,
phospholipase Cγ2 or cytosolic phospholipase A2, mitogen-activated protein kinase (MAPK) [p
38 MAPK, extracellular
signal-regulated kinase (ERK)], and blood coagulation time in rats were investigated. In vivo effects of WIB-801CE
on collagen plus epinephrine-induced acute pulmonary thromboembolism, and tail bleeding time in mice were
also inquired. In vitro effects of WIB-801CE on cytotoxicity, and fibrin clot retraction in human platelets, and nitric
oxide (NO) production in RAW264.7 cells or free radical scavenging activity were studied.
Results: Cordycepin-enriched WIB-801CE inhibited ex vivo platelet aggregation, TXA2 production, AA release,
TXAS activity, serotonin release, and p38 MAPK and ERK2 phosphorylation in collagen- and ADP-activated rat
platelets without affecting blood coagulation. Furthermore, WIB-801CE manifested in vivo inhibitory effect on
collagen plus epinephrine-induced pulmonary thromboembolism mice model. WIB-801CE inhibited in vitro NO
production and fibrin clot retraction, but elevated free radical scavenging activity without affecting cytotoxicity
against human platelets.
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Conclusion: WIB-801CE inhibited collagen- and ADP-induced platelet activation and its associated thrombus
formation ex vivo and in vivo. These were resulted from down-regulation of TXA2 production and its related AA
release and TXAS activity, and p38 MAPK and ERK2 activation. These results suggest that WIB-801CE has therapeutic
potential to treat platelet activation-mediated thrombotic diseases in vivo.
Keywords: WIB-801CE, Cordycepin, Platelet aggregation, TXA2, Serotonin, Thromboxane A2 synthase, Arachidonic
acid release, p38 MAPK, ERK2, ThrombusBackground
A species of the fungal genus Cordyceps is known to
prescribe for inflammatory and cancer disease [1, 2]. It is
reported that cordycepin (3'-deoxyadenosine, Fig. 1a), a
major component of Cordyceps militaris, has in vitro
antithrombotic effects by attenuating [Ca2+]i level and
thromboxane A2 (TXA2) production in collagen-induced
human platelet aggregation [3]. However, there is no
evidence or report concerning ex vivo and in vivo inhibi-
tory effect of cordycepin or cordycepin-enriched sub-
stance on platelet activation.
In this study, to resolve this doubtful point, we prepared
cordycepin-enriched WIB-801CE (Compound from 2008
First Project of Bioteam, Whanin Pharm. Co., Ltd., Suwon,
Korea), an ethanol extract from Cordyceps militaris-hypha.
Next, to observe whether WIB-801CE has endogenous
inhibitory effects on platelet activation associated with
thrombus formation, we orally administered WIB-801CE to
rat, and subsequently investigated the effects on major mol-
ecules associated with Ca2+ increase [4–7], arachidonic acid
(AA) release [4, 6, 8–10], TXA2 production [4, 5, 8, 11–13]
and serotonin release [13–16].Methods
Materials
WIB-801CE was provided from Whanin Pharmaceutical
Corporation (Suwon, Korea). Collagen, adenosine di-
phosphate (ADP) and thrombin were obtained from
Chrono-Log Corporation (Havertown, PA, USA). Serotonin
enzyme-linked immunosorbent assay (ELISA) kit was
purchased from Labor Diagnostika Nord GmbH &
Corporation (Nordhorn, Germany). Pure cordycepin,
aspirin, protease inhibitor cocktail, 2,2-diphenyl-1-
picrylhydrazyl (DPPH), ascorbic acid (AC), and other
reagents were obtained from Sigma Chemical Corporation
(St. Louis, MO, USA). Thromboxane B2 (TXB2) enzyme
immunoassay (EIA) kit, cyclooxygenase-1 (COX-1) fluores-
cent activity assay kit, lactate dehydrogenase (LDH) cyto-
toxicity assay kit, ozagrel and prostaglandin H2 (PGH2) for
TXA2 synthase (TXAS) assay were purchased from
Cayman Chemical (Ann Arbor, MI, USA). Arachidonic
acid (AA) release ELISA kit was purchased from Cusabio
Biotech Corporation (Wuhan, Hubei, China). Anti-
phosphor-cytosolic phospholipase A2 (cPLA2) (Ser
505),anti-phosphor-phospholipase Cβ3 (PLCβ3) (Ser
537),
anti-phosphor-phospholipase Cβ3 (PLCβ3) (Ser
1105),
anti-phosphor-phospholipase Cγ2 (PLCγ2) (Tyr
1217),
anti-phosphor-p38 MAPK, anti-phosphor-extracellular sig-
nal–regulated kinase (ERK) (1/2), anti-p38 MAPK, anti-ERK
(1/2) and anti-rabbit immunoglobulin G (IgG)-horseradish
peroxidase conjugate (HRP), and lysis buffer were obtained
from Cell Signaling (Beverly, MA, USA). Polyvinylidene
difluoride (PVDF) membrane was from General Electric
Healthcare (Piseataway, NJ, USA). Enhanced chemilu-
minescence solution (ECL) was from General Electric
Healthcare (Chalfont St. Giles, Buckinghamshire, UK).
Prothrombin time (PT) assay reagent and activated partial
thromboplastin time (APTT) assay reagent were obtained
from Fisher Diagnostics (Middletown, VA, USA).
Preparation of WIB-801CE
Cordyceps militaris was cultivated, and culture-solution
of Cordyceps militaris-hypha was concentrated up to 50°
Brix with a rotary vacuum evaporator (Eyela N3000,
Rikakikai Co., Ltd., Tokyo, Japan) at 60 °C. The Brix
was measured with refractometer (Atago Co., Ltd.,
Tokyo, Japan). The concentrate was extracted by
extraction-shaker (Cosmos 660, Kyungseo Co., Ltd.,
Seoul, Korea) for 4 h at 40 °C one time with distilled
water/95% ethanol (1:3.5, v/v), which was filtered one
time using a filter paper (Advantec No.2). The filtrate
was completely concentrated at 60 °C by an evaporator
(Eyela N3000, Rikakikai Co., Ltd., Tokyo, Japan) under re-
duced pressure, and was lyophilized and stored at -20 °C
until used. This was named as cordycepin-enriched
WIB-801CE.
Analysis of cordycepin in WIB-801CE with HPLC
WIB-801CE was dissolved with 75% methanol, then ana-
lyzed by high performance liquid chromatography (HPLC).
An Alliance 2695 liquid chromatography system (Waters
Co., Milford, MA, USA), equipped with vacuum degasser,
quaternary gradient pump, autosampler and photodiode
array detector, was connected to Empower software. A
hydrosphere C18 column (250 mm × 4.6 mm id, 5 μm,
YMC Co., Ltd., Kyoto, Japan) was used at a column
temperature of 30 °C. The applied-mobile phase gradient
program was 0.01 M KH2PO4/methanol (95:5, v/v) at
Fig. 1 Composition of cordycepin in WIB-801CE and effects of cordycepin and WIB-801CE on cytotoxicity and platelet activation. a Chemical
structure of cordycepin (3'-deoxyadenosine). b The chromatogram of WIB-801CE. c The chromatogram of pure cordycepin. d In vitro effects of
WIB-801CE and cordycepin on cytotoxicity. e In vitro effects of WIB-801CE and cordycepin on platelet aggregation without agonists. Measurements of
cordycepin, cytotoxicity, and platelet aggregation were carried out as described in “Methods” section. As a positive control to LDH cytotoxicity and
platelet activation, 0.2% triton X-100 and collagen (10 μg/mL) were used, respectively. The data are expressed as the mean ± standard deviation (n = 4).
NS, not significant versus without WIB-801CE and cordycepin, each control
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at 20 min and held for 6 min; 0.01 M KH2PO4/methanol
(95:5, v/v) at 27 min and held 6 min for chromatographic
balance. In this step, 99.8% of methanol was used. The
flow rate was at 1.0 mL/min and sample injection volume
was 10 μL. The ultra violet detection was operated at
254 nm.Animals and administration
We investigated the ex vivo and in vivo effects of WIB-
801CE using rats (Sprague-Dawley, male, 200 g) and
Institute of Cancer Research (ICR) mice (male, 18 g,
Daehan Biolink Co., Ltd., Chungbook, Korea). Rats for
ex vivo experiment and mice for in vivo observation
were divided into as follows, respectively: WIB-801CE-nontreated group (control), WIB-801CE-treated group,
aspirin-treated group as positive control of in vivo, and
warfarin-treated group as positive control of ex vivo.
Animals were acclimatized for a week at a temperature
of 24 ± 1 °C and humidity of 55 ± 5%. Before oral adminis-
tration of substances, all animals were fasted for 12 h, then
were fed with standard pellets diet (Purina Inc., Korea)
had free access to water. WIB-801CE [200, 400 mg/kg-
body weight (BW)] and warfarin (1 mg/kg-BW) for ex vivo
experiment were orally administered to the rats one per
day for seven days, and WIB-801CE (200, 400 mg/kg-BW)
and aspirin (100 mg/kg-BW) for in vivo observation were
orally administered to the mice once a day for five days.
200 mg/kg-BW of WIB-801CE is corresponded to the
minimum dose that inhibits rat platelet aggregation (data
not shown). WIB-801CE, warfarin, and aspirin were
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by the Ethics Committee for Animal Experiments of
Whanin Pharmaceutical Corporation (Suwon, Korea/
15-NE-016 for rats, 15-NE-008 for mice).
Preparation of rat platelet-rich plasma and platelet-poor
plasma for ex vivo assay
After the final respective administration, all rats were
fasted for 24 h, then after 2 h of WIB-801CE- and
warfarin-administration were anesthetized with 20% ur-
ethane before sacrifice according to the method of
Zhang et al. [17]. The blood was collected from the ab-
dominal aorta. The blood was anti-coagulated with acid-
citrate-dextrose solution (0.8% citric acid, 2.2% sodium
citrate, 2.45% glucose), and was centrifuged at 250 × g
for 10 min in order to obtain platelet-rich plasma (PRP).
In order to remove residual red blood cells and white
cells, the PRP was again centrifuged at 125 × g for
10 min. Platelet-poor plasma (PPP) was prepared by
centrifuging the part of PRP at 1,300 × g for 10 min.
PRP was used to investigate ex vivo platelet aggregation,
TXA2 production, serotonin release, COX-1 and TXAS
activities, AA release and protein phosphorylation. PPP
was used to investigate ex vivo PT and APTT. The number
of platelets in PRP was adjusted with PPP to a final con-
centration of 5 × 108/mL. All of the above procedures were
carried out at 25 °C to avoid platelet aggregation from any
effect of low temperature.
Preparation of human PRP and washed platelets for
in vitro assay
To investigate in vitro effects of WIB-801CE and cor-
dycepin on fibrin clot retraction, we used human PRP
and washed platelets. PRP from normal healthy human
volunteers with informed consent was obtained from
the Korean Red Cross Blood Center (KRBC, Changwon,
Korea), and its experimental use was approved by the
KRBC (Safety Supervisor Team-621-2015.02.26) and the
Korea National Institute for Bioethics Policy Public
Institutional Review Board (Seoul, Korea/PIRB12-072-01)
with informed consent. PRP anticoagulated with acid-
citrate-dextrose solution (0.8% citric acid, 2.2% sodium
citrate, 2.45% glucose) was centrifuged for 10 min at
125 × g to remove a little red blood cells and white cells,
which was used to investigate the effect of WIB-801CE
and cordycepin on thrombin-induced fibrin clot retrac-
tion. The number of platelets in PRP was adjusted with
PPP to a final concentration of 5 × 108/mL.
To observe in vitro effects of WIB-801CE and cordy-
cepin on cytotoxicity and resting platelet aggregation, we
prepared human washed platelets. The PRP was centri-
fuged for 10 min at 1,300 × g to obtain platelet pellets.
The platelets were washed twice with washing buffer
(138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mMNaH2PO4, 5.5 mM glucose, and 1 mM Na2EDTA, pH 6.5).
The washed platelets were then resuspended in suspension
buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3,
0.36 mM NaH2PO4, 0.49 mM MgCl2, 5.5 mM glucose,
0.25% gelatin, pH 6.9) to a final concentration of 5 ×
108/mL. All of the above procedures were carried out
at 25 °C to avoid platelet aggregation from any effect of
low temperature. The Korea National Institute for Bio-
ethics Policy Public Institutional Review Board (Seoul,
Korea/PIRB12-072-01) approved these experiments.
In vitro cytotoxicity assay
Platelet cytotoxicity was determined by leakage of LDH
from cytosol. Human washed platelets (108/mL) were in-
cubated for 5 min at 37 °C in the presence of WIB-801CE
or cordycepin, then centrifuged with 12,000 × g at room
temperature for 2 min. The supernatant was measured
with a synergy HT multi-model microplate reader (BioTek
Instruments, Winooski, VT, USA) using LDH assay kit.
LDH leakage was expressed as percentage of total LDH
activity in platelets completely lysed by 0.2% triton X-100.
Measurement of ex vivo rat platelet aggregation, and
in vitro human resting platelet aggregation
To evaluate antiplatelet effect of WIB-801CE under condi-
tion that generates maximally platelet aggregation, we used
high dose of collagen and ADP as agonists. The con-
centration of collagen-induced maximal rat (Sprague-
Dawley, male) platelet aggregation was 10 μg/mL [18],
and 5 μM of ADP was used to aggregate rat platelets
[19]. Accordingly, we used 10 μg/mL of collagen, and
5 μM of ADP to cause ex vivo rat platelet aggregation.
To measure ex vivo rat platelet aggregation, PRP (108
platelets/mL) were preincubated with or without WIB-
801CE for 3 min at 37 °C, then stimulated for 5 min by
collagen (10 μg/mL) and ADP (5 μM) using an aggreg-
ometer (Chrono-Log Corporation, Havertown, PA, USA)
at a constant stirring speed of 1,000 rpm.
To observe in vitro effects of WIB-801CE and cordycepin
on resting human platelet aggregation, the aggregation of
human washed platelets (108/mL) was performed as
described above in the presence of WIB-801CE or cor-
dycepin without agonists. But, collagen (10 μg/mL) was
used as positive control. Each aggregation rate was de-
termined as an increase in light transmission. The PPP
for PRP aggregation, and platelet suspension buffer
(pH 6.9) for washed platelet aggregation were used as
the reference (transmission 0) to regulate the base line
of aggregometer. WIB-801CE and cordycepin were dis-
solved in distilled water.
Ex vivo measurement of TXB2
To investigate the effect on TXA2 production, the aggrega-
tion was terminated by adding ice-cold 5 mM EDTA and
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AA to TXA2. The amounts of TXB2, a stable metabolite of
TXA2, were determined using a TXB2 EIA kit according to
the procedure described by the manufacturer.
Ex vivo Western blot for analysis of protein
phosphorylation
Collagen- and ADP-activated rat PRP was centrifuged
for 10 min at 1,300 × g under 4 °C to remove PPP and
get platelet pellets. The platelets were suspended twice
with suspension buffer (138 mM NaCl, 2.7 mM KCl,
12 mM NaHCO3, 0.36 mM NaH2PO4, 0.49 mM MgCl2,
5.5 mM glucose, 0.25% gelatin, pH 7.4). The suspended
platelets (250 μL) were lysed by adding an equal volume
(250 μL) of lysis buffer [20 mM Tris-HCl, 150 mM NaCl,
1 mM Na2EDTA, 1 mM EGTA, 1% triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerophosphate (serine/
threonine phosphatase inhibitor), 1 mM Na3VO4 (ATPase,
alkaline and acid phosphatase, and protein phosphotyrosine
phosphatase inhibitor), 1 μg/mL leupeptin (serine and cyst-
eine protease inhibitor), and 1 mM phenylmethanesulfonyl
fluoride (serine protease and acetylcholinesterase inhibitor),
pH 7.5].
Platelet lysates were suspended in their equal volume of
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) buffer (62.5 mM Tris-HCl, 10% glycerol, 1%
SDS, 1% β-mercaptoethanol, 0.01% bromphenol blue,
pH 6.8), then were boiled to completely denature the pro-
teins for 5 min. Aliquots containing 15 μg of protein from
each sample tube were subjected to SDS-PAGE (8%,
1.5 mm gel) according to the method of Laemmli [20].
Proteins in the gel were transferred to PVDF membrane
in the presence of transfer buffer (25 mM Tris-HCl,
192 mM glycine, 20% methanol, pH 8.3). PVDF mem-
brane was washed one time for 5 min with Tris-buffered
saline with tween 20 (25 mM Tris-HCl, 140 mM NaCl,
2.7 mM KCl, 0.1% tween 20, pH 7.4), then was blocked
with blocking buffer (25 mM Tris-HCl, 140 mM NaCl,
2.7 mM KCl, 0.1% tween 20, 5% skim milk, pH 7.4) for
1 h at room temperature, and subsequently was washed
three times for 5 min.
The protein phosphorylation was observed using
Western blotting. The dilutions for 1st antibody (anti-phos-
phor-cPLA2, anti-phosphor-PLCβ3, anti-phosphor-PLCγ2,
anti-phosphor-p38 MAPK, anti-phosphor-ERK, anti-p38 MAPK,
anti-ERK) and 2nd antibody (anti-rabbit IgG-HRP) were
1:1,000 and 1:10,000, respectively. The membranes were vi-
sualized using ECL. Blots were analyzed using the Quantity
One, Ver. 4.5 (BioRad, Hercules, CA, USA).
Ex vivo determination of AA release
To investigate the effect on AA release, the aggregation
was terminated adding ice-cold 5 mM EDTA and 0.2 mM
indomethacin to inhibit subsequent conversion of AA toTXA2, and centrifuged with 200 × g at 4 °C for 10 min.
The supernatants were used for the assay of AA release.
AA release was measured with a Synergy HT multi-model
microplate reader (BioTek Instruments, Winooski, VT,
USA) using AA release ELISA kit.
Preparation of platelet lysates
We prepared platelet lysates to determine ex vivo COX-
1 and TXAS activities. Collagen- and ADP-activated rat
PRP was centrifuged for 10 min at 1,300 × g to remove
PPP and get platelet pellets. The platelets were then sus-
pended twice with suspension buffer (138 mM NaCl,
2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4,
0.49 mM MgCl2, 5.5 mM glucose, 0.25% gelatin, pH 7.4).
The suspended platelets in the presence of 1% protease in-
hibitor cocktail were sonicated ten times in sensitivity
100% for 20 s at 4 °C with a sonicator (HD 2070, Bandelin
Electronic, Bandelin, Germany) to obtain platelet lysates.
Next, the platelet lysates were centrifuged at 12,000 × g
for 15 min at 4 °C to remove cell debris. The supernatant
was used to measure COX-1 and TXAS activity.
Ex vivo measurement of COX-1 activity
Platelet lysates containing 10 μg of protein were used.
COX-1 activity was measured with a Synergy HT multi-
model microplate reader (BioTek Instruments, Winoo-
ski, VT, USA) using COX-1 fluorescent activity assay kit
according to the procedure described by manufacturer.
Ex vivo measurement of TXAS activity
Platelet lysates containing 20 μg of protein were used.
The reaction for assay of TXAS activity was initiated by
the addition of TXAS substrate PGH2 and allowed to
proceed for 1 min at 37 °C. The reaction was terminated
by the addition of 1 M citric acid, then was neutralized
with 1 N NaOH. The concentration of TXA2 was deter-
mined as TXB2, a stable metabolite of TXA2, which was
measured with a Synergy HT multi-model microplate
reader (BioTek Instruments, Winooski, VT, USA) using
TXB2 EIA kit.
Ex vivo determination of serotonin release
To investigate the effect on serotonin release, the aggre-
gation was centrifuged at 4 °C for 10 min at 200 × g. The
supernatants were used for the assay of serotonin re-
lease. Serotonin release was measured with a Synergy
HT multi-model microplate reader (BioTek Instruments,
Winooski, VT, USA) using serotonin ELISA kit.
Ex vivo measurement of PT and APTT
To investigate whether WIB-801CE shows anticoagulant
characteristics, if any, has bleeding risk as side effect of
anticoagulant [21], we measured PT and APTT, markers
of blood coagulation. The PPP (100 μL) was preincubated
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Co., KG, Norderstedt, Germany) cup (catalog number 95-
662, BioMérieux, Marcyl’Etoile, France) with gentle stir-
ring for 1 min at 37 °C. PT was determined as the time
interval between the addition of PT reagent (100 μL) to
the PPP and the formation of a fibrin clot. After preincu-
bation of PPP for APTT measurement, 100 μL of APTT
reagent was added to the PPP (100 μL) and incubated for
3 min at 37 °C. Following incubation, 100 μL of 25 mM
CaCl2 was immediately added to the PPP containing
APTT reagent. APTT was determined as the time re-
quired to form a fibrin clot.
In vivo tail bleeding time assay
We investigated whether WIB-801CE has bleeding risk,
the side effect of antiplatelet substance [21]. WIB-801CE
(200, 400 mg/kg-BW) and aspirin (100 mg/kg-BW), a
positive control, were orally administered to mice once a
day for five days. In this study, we used mice for measur-
ing tail bleeding time according to the method of Kim
and Lee [22]. After 5 min of the respective final adminis-
tration, mice were anesthetized with zoletil (40 mg/kg,
i.p.). The distal 0.5 cm segment of the tail was transected
with operating knife, and immediately immersed in a tube
containing 37 °C of saline. Tail bleeding time was deter-
mined as the time required to cause blood coagulation.
In vivo evaluation of anti-acute pulmonary
thromboembolism
To confirm the endogenous antithrombotic effect, we
used a mice model to generate acute pulmonary thrombo-
embolism [23]. Mice were orally administered with WIB-
801CE (200, 400 mg/kg-BW), and aspirin (100 mg/kg-BW).
After 1 h of respective administration, the mixture (100 μL)
of collagen (300 μg/kg-BW) plus epinephrine (30 μg/kg-
BW) were injected via tail vein, and the rate of protection
and mortality was observed for 15 min, which were calcu-
lated as follow: 1) Protection rate (%) = [(Number of tested
mice – Number of dead mice)/Number of tested mice] ×
100. 2) Mortality rate (%) = [Number of dead mice/Number
of tested mice] × 100. These experiments were proved by
the Ethics Committee for animal experiments of Whanin
Pharmaceutical Corporation (Suwon, Korea/15-NE-009).
In vitro assay of platelet-mediated fibrin clot retraction
We investigated whether WIB-801CE or cordycepin in-
hibits fibrin clot retraction, an index of thrombi formation
[24]. Human PRP 250 μL (108 platelets/mL) were trans-
ferred into polyethylene tube to avoid clot adherence, then
were preincubated with or without WIB-801CE or cordy-
cepin for 10 min at 37 °C, and subsequently stimulated
with thrombin (0.5 U/mL) for 60 min at 37 °C. Pictures of
fibrin clot were taken at 0 and 60 min using a digital
camera, and its quantification was carried out bymeasurement of clot area using the NIH Image J Soft-
ware (V1.46, National Institutes of Health, USA). Per-
centage of clot retraction was calculated as follows:
Retraction (%) by thrombin = [1 - (final clot area/initial
clot area)] × 100.
In vitro nitric oxide assay
To observe antiinflammatory effect of WIB-801CE, we
used mouse leukemic macrophage RAW264.7 cells.
RAW264.7 cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA),
and were maintained at 37 °C in 5% CO2 and 95% air
in Dulbecco’s Modified Eagle’s Medium (GE Healthcare,
Marlborough, USA) containing 10% fetal bovine serum,
and 1% penicillin-streptomycin solution. RAW264.7 cells
(5 × 104 cells) were preincubated for 30 min with or with-
out WIB-801CE, or inducible nitric oxide synthase (iNOS)
inhibitor amino guanidine (AG), and stimulated for 24 h
by lipopolysaccharide (10 ng/mL). The supernatant was
used for NO assay using Griess reagent. Equal volume of
culture supernatant (80 μL) and Griess reagent (80 μL)
were mixed. The absorbance of the mixture was measured
at 540 nm using spectrophotometer (Spectramax 190,
Molecular devices, LLC., Sunnyvale, CA, USA). Nitrite
was used as standard of NO.
Ex vivo nitric oxide assay
To investigate the NO production, we used collagen-
and ADP-stimulated PRP obtained from rats adminis-
tered with the WIB-801CE (200, 400 mg/kg-BW). The
PRP was centrifuged at 4 °C for 10 min at 10,000 × g to
get plasma. The plasma was incubated 1 h with 400 μL
methanol:diethylether (3:1 mixture v/v), and subsequently
plasma proteins were precipitated by centrifuging at 4 °C
for 10 min at 10,000 × g. The supernatant was used for
NO assay using Griess reagent. Equal volume of super-
natant (80 μL) and Griess reagent (80 μL) were mixed.
After 30 min, absorbance of the mixture was measured at
540 nm using a Synergy HT multi-model microplate
reader (BioTek Instruments, Winooski, VT, USA). Nitrite
was used as standard of NO.
In vitro determination of antioxidant activity
To obtain antioxidant effect of WIB-801CE, we mea-
sured scavenging activity of free radical in DPPH accord-
ing to the method [25, 26]. DPPH was dissolved in 99%
ethanol to make 200 μM of solution. WIB-801CE and
antioxidant AC were dissolved in distilled water. Equal
volume of test substances and DPPH were mixed at
room temperature. After 30 min, the reduction in DPPH
absorbance at 517 nm was measured using spectrophotom-
eter (Optizen 2120UV, Mecasys, Korea). The scavenging
activity of DPPH radicals by substances was determined
using the following equation [26]: Scavenging activity (%) =
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99% ethanol, DPPH vehicle, and distilled water, vehicles of
WIB-801CE and AC was 0.001 and 0.000.
Ex vivo measurement of cordycepin effect on rat platelet
aggregation
This experiment was performed to investigate the effect
of cordycepin on ex vivo platelet aggregation. When cor-
dycepin (15 mg/kg per day) was administered orally to
the mice for 14 days, antitumor activity was known to
observe [27]. Therefore, we selected 5 and 10 mg/kg-BW
per day of cordycepin in this experiment as moderate doses
for administration. These doses are corresponded to about
36 and 72% of cordycepin in WIB-801CE (200 mg/kg-BW)
that inhibited ex vivo rat platelet aggregation. Rats
(Sprague-Dawley, male, 200 g) were acclimatized for a
week at a temperature of 24 ± 1 °C and humidity of 55 ±
5%. Before oral administration of cordycepin, rats were
fasted for 12 h, then were fed with standard pellets diet
(Purina Inc., Korea) had free access to water. Cordycepin (5
and 10 mg/kg-BW) was orally administered to the rats one
per day for seven days. Cordycepin were dissolved with dis-
tilled water. The experiments were proved by the Ethics
Committee for Animal Experiments of Whanin Pharma-
ceutical Corporation (Suwon, Korea/15-NE-016 for rats).
After the final respective administration, all rats were fasted
for 24 h, then were anesthetized with 20% urethane before
sacrifice. PRP preparation, platelet aggregation, measure-
ment were performed as described before.
Protein assay
To determine COX-1, TXAS activity, and protein phos-
phorylation, protein concentration was measured using
bicinchoninic acid assay kit (Pierce Biotechnology, USA).
Statistical analyses
The experimental results are indicated as the mean ± stand-
ard deviation accompanied by the number of observations.
Data were determined by analysis of variance (ANOVA). If
this analysis showed significant differences among the
group means, then each group was compared by the
Newman-Keuls method. Statistical analysis was carried
out according to the SPSS 21.0.0.0 (SPSS, Chicago, IL,
USA). p < 0.05 was considered to be statistically significant.Table 1 Content of cordycepin in WIB-801CE
Retention time (min) Area (mAU × s) Concentration o
Pure cordycepin 19.980 2,949.35 100.30
WIB-801CE Peak 1 19.988 ± 0.011 2,278.34 ± 13.77 1,006 ± 0.32
The content of cordycepin in WIB-801CE was expressed using the following equ
(concentration of pure cordycepin/concentration of WIB-801CE) × [(100% - % o
100%) × 100%. Water content of pure cordycepin was 8.18%. Purity of pure cordycepinResults
Composition of cordycepin in WIB-801CE
Because it is known that Cordyceps militaris, a source of
WIB-801CE, has cordycepin (Fig. 1a) [28], we analyzed
cordycepin of WIB-801CE with HPLC. As shown in Fig. 1b,
peak 1 from WIB-801CE was observed at 19.988 min of
the retention time, which was almost in accord with the
retention time (19.980 min) of pure cordycepin (Fig. 1c).
This means that peak 1 is derived from cordycepin in
WIB-801CE. The concentration of peak 1 in WIB-
801CE corresponding to cordycepin was 69.30 ± 0.20 mg/g-
WIB-801CE (about 6.93 ± 0.02%, Table 1). Whole fruiting
body myelia of Cordyceps militaris is known to contain
0.16% of cordycepin, but whole fruiting body, stroma, and
larva of Cordyceps sinensis do not contain cordycepin [29].
Therefore, the cordycepin content in WIB-801CE that we
used in this study is very higher than those in whole fruiting
body myelia of Cordyceps militaris, and in whole fruiting
body, stroma, and larva of Cordyceps sinensis.In vitro effects of WIB-801CE and cordycepin on cytotoxicity
against resting human platelets
Cytotoxicity of drugs or substances is evaluated by cyto-
solic LDH leakage, which is different from platelet aggre-
gation or granule secretion by platelet agonists, but is
released upon damage of cell membrane [30–32]. There-
fore, we investigated the effect of WIB-801CE on LDH
leakage to human platelets. When human washed plate-
lets (108/mL) were treated by membrane detergent triton
X-100, LDH was potently released up to 268.6 ± 4.4 mU/
108 platelets, which is expressed as 100% (Fig. 1d). LDH
leakage by WIB-801CE (200, 400 μg/mL) was not oc-
curred, and its degree (8.6 ± 1.4%) by 400 μg/mL of
WIB-801CE was not significantly different from that
(7.3 ± 0.4%) by resting platelets (Fig. 1d). Because WIB-
801CE contains 6.93 ± 0.02% of cordycepin (Table 1), to
investigate whether cordycepin has cytotoxicity, we used
concentrations (56, 112 μM) of cordycepin (MW 251.14)
corresponding to cordycepin concentration (6.93 ± 0.02%)
that contains in WIB-801CE (200, 400 μg/mL). As the re-
sults, cordycepin (56, 112 μM) did not affect the release of
LDH as compared with that (7.3 ± 0.4%) by resting platelets
(Fig. 1d). These mean that WIB-801CE and cordycepin do
not affect the cytotoxicity to human resting platelets.f sample (μg/mL) Cordycepin content (%) Content (mg/g-WIB-801CE)
- -
6.93 ± 0.02 69.30 ± 0.20
ation: Cordycepin content (%) = (area of peak 1/area of pure cordycepin) ×
f water content of cordycepin)/100%] × (% of purity of pure cordycepin/
was 98.0%. The data are given as the mean ± standard deviation (n = 3)
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of resting human platelets
Platelet activation is an index of platelet shape change, plate-
let aggregation and granule secretion, and is the cause of
cardiovascular and cerebrovascular disease, and atheroscler-
osis [33–35]. Accordingly, if WIB-801CE activates resting
platelets, unstimulated platelets, a question to evaluate the
antiplatelet effects of WIB-801CE might be raised. There-
fore, the effect of WIB-801CE and cordycepin on platelet ac-
tivation was determined by measuring platelet aggregation
in resting human platelets. As the results, a positive control
collagen (10 μg/mL) activated platelets by increasing platelet
aggregation up to 83.3 ± 3.1% (Fig. 1e). However, WIB-
801CE (200, 400 μg/mL) alone, and cordycepin (56,
112 μM) alone did not increased platelet aggregation
(Fig. 1e), as compared with that (1.0 ± 1.0%) by resting plate-
lets. It was evidenced that WIB-801CE and cordycepin alone
do not affect the activation of resting human platelets.
Ex vivo effects of WIB-801CE on platelet aggregation and
TXA2 production
It is known that the inhibition of collagen- and ADP-
induced platelet aggregation is potential target to developa
c
Fig. 2 Ex vivo effects of WIB-801CE on platelet aggregation and TXB2 prod
aggregation. b Ex vivo effects of WIB-801CE on ADP-induced platelet aggre
production. d Ex vivo effects of WIB-801CE on ADP-induced TXB2 productio
The data are expressed as the mean ± standard deviation (n = 6 to 10). *p <
ADP-stimulated platelets in the presence of WIB-801CE 200 mg/kg-BW. 1) Δ (%
(%) = [(agonist +WIB-801CE 400 mg/kg-BW) – agonist]/agonist × 100antithrombotic agent having antiplatelet characteristics
[36, 37]. Therefore, we used on collagen and ADP as
agonists. When PRP (108/mL) from control was acti-
vated with collagen and ADP, the aggregation rate was
increased up to 82.9 ± 6.6% by collagen (Fig. 2a) and 78.7 ±
4.9% by ADP (Fig. 2b). However, collagen- and ADP-
induced rat platelet aggregation was significantly atten-
uated by WIB-801CE (200, 400 mg/kg-BW) (Fig. 2a
and b). The inhibitory degrees by 200 mg/kg-BW were
13.0% to that by collagen (Fig. 2a) and 10.9% against
that by ADP (Fig. 2b).
We investigated next whether WIB-801CE involves in
inhibition of TXA2 production to attenuate collagen- and
ADP-induced rat platelet aggregation. When PRP (108/mL)
from control was activated by collagen and ADP, the TXA2
(determined as TXB2, a stable metabolite of TXA2) was in-
creased to 615.0 ± 11.5 ng/108 platelets (Fig. 2c) by collagen
and 11.5 ± 1.6 ng/108 platelets by ADP (Fig. 2d). However,
collagen- and ADP-produced TXA2 were inhibited by
WIB-801CE (Fig. 2c and d). The inhibitory degrees by
200 mg/kg-BW were 30.7% against that by collagen (Fig. 2c)
and 37.3% to that by ADP (Fig. 2d). WIB-801CE (400 mg/
kg-BW) inhibited weakly ADP-induced platelet aggregationb
d
uction. a Ex vivo effects of WIB-801CE on collagen-induced platelet
gation. c Ex vivo effects of WIB-801CE on collagen-induced TXB2
n. Measurements were carried out as described in “Methods” section.
0.05 versus the each agonist-stimulated platelets, #p < 0.05 versus the
) = [(agonist +WIB-801CE 200 mg/kg-BW) – agonist]/agonist × 100, 2) Δ
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those by WIB-801CE (200 mg/kg-BW).
Ex vivo effects of WIB-801CE on phosphorylation of
PLCβ3, PLCγ2, cPLA2, release of AA, and activity of COX-1
and TXAS
The reduction of TXA2 by WIB-801CE is connected to ei-
ther inhibition of AA release enzymes (PLCβ, PLCγ and
cPLA2) or AA utilization enzymes (COX-1, TXAS). When
PRP (108/mL) from WIB-801CE (200, 400 mg/kg-BW)
rats were activated by collagen and ADP, phosphorylation
of PLCβ3 (Ser
1105), PLC γ2 (Tyr
1217) and cPLA2 (Ser
505)
were increased (Fig. 3a and b, lane 2), but PLCβ3 (Ser
537)
was not changed as compared with those (Fig. 3a and b,
lane 1) by resting platelets. WIB-801CE did not inhibit
these phosphorylation (Fig. 3a and b, lane 3 and 4). These
results are indicated that WIB-801CE does not attenuate
collagen- and ADP-induced the activities of cPLA2, PLCβ3
and PLCγ2, and the direct AA release by cPLA2, but may
involve in inhibition of the indirect AA release by PLCβ3/
diacylglycerol (DG)- and monoacylglycerol-lipase pathway
[4, 5, 11, 12].
With this possibility, we investigated whether WIB-
801CE affects AA release. Collagen and ADP released AA
up to 91.5 ± 0.7 ng/108 platelets (Fig. 3c) and 49.4 ± 0.4 ng/
108 platelets (Fig. 3d) in control, respectively. However,
when PRP (108/mL) from WIB-801CE (200, 400 mg/kg-
BW) rats were activated by collagen and ADP, the levels of
AA release were significantly decreased as compared with
those by control (Fig. 3c and d). The inhibitory degrees by
200 mg/kg-BW were 29.0% (Fig. 3c) against that by colla-
gen and 35.2% (Fig. 3d) against that by ADP.
WIB-801CE did not completely inhibit AA release (Fig. 3c
and d), which means that collagen- and ADP-released AA
may be subsequently metabolized to TXA2 via COX-1/
TXAS pathway. Therefore, we investigated whether WIB-
801CE inhibits ex vivo activity of COX-1 or TXAS. Collagen-
and ADP-induced COX-1 activities as compared with those
by resting platelets, but these were not attenuated by WIB-
801CE (200, 400 mg/kg-BW) (Fig. 3e). Collagen and ADP in-
duced TXAS activities as compared with those by resting
platelets (Fig. 3f and g). However, collagen-induced TXAS
activity (18.8 ± 1.9 ng/protein-mg/min) was reduced to
34.6% (12.3 ± 1.1 ng/protein-mg/min) by WIB-801CE
(200 mg/kg-BW) (Fig. 3f). ADP-induced TXAS activity (5.9
± 0.5 ng/protein-mg/min) was also attenuated to 27.1% (4.3
± 0.5 ng/protein-mg/min) by WIB-801CE (200 mg/kg-BW)
(Fig. 3g). WIB-801CE (400 mg/kg-BW) inhibited weakly
ADP-induced AA release (Fig. 3d) and TXAS activity (Fig. 3g)
as compared with those by WIB-801CE (200 mg/kg-BW).
Ex vivo effects of WIB-801CE on serotonin release
Next, we investigated the effect of WIB-801CE on sero-
tonin release as an index of granule secretion. Collagen andADP elevated serotonin release up to 224.5 ± 4.3 ng/108
platelets (Fig. 4a) and 290.1 ± 9.6 ng/108 platelets (Fig. 4b),
respectively. On the contrary, collagen- and ADP-released
serotonin levels were reduced by WIB-801CE (200,
400 mg/kg-BW) (Fig. 4a and b). The inhibitory degrees by
200 mg/kg-BW were 66.3% to that by collagen (Fig. 4a) and
60.2% against that by ADP (Fig. 4b). WIB-801CE
(400 mg/kg-BW) weakly inhibited ADP-induced sero-
tonin release (Fig. 4b) as compared with that by WIB-
801CE (200 mg/kg-BW).
Ex vivo effects of WIB-801CE on p38 MAPK- and
ERK-phosphorylation
It is well reviewed that platelets contain MAPKs such as
p38, ERK (1/2), and c-Jun N-terminal kinase [38]. These
are activated by various agonists (i.e. collagen, ADP,
thrombin, von Willebrand factor, fibrinogen) and subse-
quently stimulate various enzymes [myosin light chain
kinase (MLCK), DG-lipase, cPLA2, COX-1] associated
with platelet activation [9, 10, 38–46]. Of MAPKs, p38 MAPK
and ERK2 stimulate MLCK [38–41] to release serotonin,
DG-lipase [45] and cPLA2 [9, 10, 38, 42, 43] to produce
AA, TXA2 precursor. In this study, to observe the relation-
ship with the results that WIB-801CE inhibited collagen-
and ADP-induced TXA2 production (Fig. 2c and d), AA
release (Fig. 3c and d) and serotonin release (Fig. 4a and b),
we investigated whether WIB-801CE inhibits the phosphor-
ylation of p38 MAPK and ERK.
Collagen and ADP increased potently p38 MAPK phos-
phorylation (Fig. 5a and b, lane 2) as compared with
those by resting platelets (Fig. 5a and b, line 1), respect-
ively. However, these were diminished by WIB-801CE
(200, 400 mg/kg-BW) (Fig. 5a and b, lane 3, 4). WIB-
801CE (200 mg/kg-BW) inhibited p38 MAPK phosphoryl-
ation up to 52.6% against that by collagen (Fig. 5a, lane
3) and 80.0% against that by ADP (Fig. 5b, lane 3).
Collagen and ADP elevated potently ERK2 (42 kDa)
phosphorylation (Fig. 5c and d, lane 2) as compared with
those by resting platelets (Fig. 5c and d, line 1), respect-
ively. However, these were also vanished by WIB-801CE
(200, 400 mg/kg-BW) (Fig. 5c and d, lane 3, 4). WIB-
801CE (200 mg/kg-BW) inhibited ERK2 (42 kDa) phos-
phorylation up to 62.5% against that by collagen (Fig. 5c,
lane 3) and 81.8% against that by ADP (Fig. 5d, lane 3).
WIB-801CE (400 mg/kg-BW) inhibited weakly phos-
phorylation of both p38 MAPK and ERK2 (Fig. 5b and d,
lane 4) as compared with those (Fig. 5b and d, lane 3) by
WIB-801CE (200 mg/kg-BW) in ADP-activated platelets.
Ex vivo and in vivo effects of WIB-801CE on blood
coagulation and tail bleeding time
Bleeding is connected to the attenuation of platelet aggre-
gation and blood coagulation, and the inhibition of throm-
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Fig. 3 Ex vivo effects of WIB-801CE on phosphorylation of cPLA2, PLCβ3, PLCγ2, release of AA, and activity of COX-1 and TXAS. a Ex vivo effects of
WIB-801CE on collagen-induced phosphorylation of cPLA2, PLCβ3 and PLCγ2. Lane 1, unstimulated platelets; Lane 2, collagen (10 μg/mL); Lane 3,
collagen (10 μg/mL) + WIB-801CE (200 mg/kg-BW); Lane 4, collagen (10 μg/mL) + WIB-801CE (400 mg/kg-BW). b Ex vivo effects of WIB-801CE on
ADP-induced phosphorylation of cPLA2, PLCβ3 and PLCγ2. Lane 1, unstimulated platelets; Lane 2, ADP (5 μM); Lane 3, ADP (5 μM) +WIB-801CE
(200 mg/kg-BW); Lane 4, ADP (5 μM) +WIB-801CE (400 mg/kg-BW). c Ex vivo effects of WIB-801CE on collagen-induced arachidonic acid release.
d Ex vivo effects of WIB-801CE on ADP-induced arachidonic acid release. e Ex vivo effects of WIB-801CE on COX-1 activity f Ex vivo effects of WIB-801CE
on collagen-induced TXAS activity. g Ex vivo effects of WIB-801CE on ADP-induced TXAS activity. Measurements were carried out as described in “Methods”
section. The data are expressed as the mean ± standard deviation (n= 4). *p< 0.05 versus each agonist-stimulated platelets. NS, not significant versus the
each agonist-stimulated platelets, #p< 0.05 versus the ADP-stimulated platelets in the presence of WIB-801CE 200 mg/kg-BW. 1) Δ (%) = [(agonist +WIB-
801CE 200 mg/kg-BW) – agonist]/agonist × 100
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APTT) and in vivo tail bleeding time as indexes of bleeding.
As shown in Table 2, both ex vivo PT and APTT were not
significantly prolonged by PPP from WIB-801CE rats as
compared with those (PT, 13.2 ± 2.3 s; APTT, 26.2 ±
4.1 s) by normal. Warfarin (1 mg/kg-BW) infinitely
prolonged PT and APTT (Table 2).
With regard to the effects of WIB-801CE on tail
bleeding time, WIB-801CE (200, 400 mg/kg-BW) sig-
nificantly prolonged from 125.3 ± 17.0 s by control to
264.8 ± 79.0 s and 360.3 ± 83.8 s, respectively (Table 3).
Aspirin (100 mg/kg-BW) also prolonged tail bleeding
time to 1,800.0 ± 0.0 s (Table 3). Aspirin (100 mg/kg-
BW) potently prolonged bleeding time to 1,336.5%, on
the other hand, WIB-801CE (200, 400 mg/kg-BW) pro-
longed it up to 111.4% and 187.5% as compared with
that (125.3 ± 17.0 s) by control, respectively (Table 3).
In vivo effects of WIB-801CE on acute pulmonary
thromboembolism
Because antiplatelet drugs play an important role in pro-
tection of thrombus formation, we investigated whether
WIB-801CE, inhibiting ex vivo platelet aggregation, has
also a protective effect on endogenous thrombus formation.
In this study, in vivo venous antithrombotic effect of WIB-a
Fig. 4 Ex vivo effects of WIB-801CE on serotonin release. a Ex vivo effects o
of WIB-801CE on ADP-induced serotonin release. Measurements were carrie
the mean ± standard deviation (n = 4). *p < 0.05 versus the each agonist-stimu
presence of WIB-801CE 200 mg/kg-BW. 1) Δ (%) = [(agonist +WIB-801CE 200 m801CE was estimated using collagen plus epinephrine-
induced acute pulmonary thromboembolism mouse model
[23, 49–51]. As shown in Table 4, when the mixture of col-
lagen plus epinephrine was treated to mice, the protection
rate was 4.2% against acute pulmonary thromboembolism,
and the mortality rate was 95.8%. However, in WIB-801CE-
treated mice, the protection degree from a pulmonary
thromboembolism was increased to 25.0% by WIB-801CE
(200 mg/kg-BW), and 35.0% by WIB-801CE (400 mg/kg-
BW) in a dose dependent manner (Table 4). In aspirin
(100 mg/kg-BW)-treated mice, the protection degree from
a pulmonary thromboembolism was increased up to 35.0%,
and the mortality was decreased to 65.0%, which were
equal to those by WIB-801CE (400 mg/kg-BW)-treat-
ment (Table 4). These mean that WIB-801CE is actually
valid to protect venous thromboembolism like aspirin.
In vitro effects of WIB-801CE and cordycepin on fibrin clot
retraction
Fibrin clot retraction is a final index of platelet aggregation-
mediated thrombotic formation, and is resulted from inter-
action of fibrin-platelet [24]. Thrombin stimulated the
retraction of fibrin clot (Fig. 6a, dotted circle), but WIB-
801CE (200, 400 μg/mL) inhibited it in a dose dependent
manner (Fig. 6a and b). WIB-801CE (200 μg/mL) inhibitedb
f WIB-801CE on collagen-induced serotonin release. b Ex vivo effects
d out as described in “Methods” section. The data are expressed as
lated platelets, #p < 0.05 versus the ADP-stimulated platelets in the
g/kg-BW) – agonist]/agonist × 100
a b
c d
Fig. 5 Ex vivo effects of WIB-801CE on phosphorylation of p38 MAPK and ERK2. a Ex vivo effects of WIB-801CE on collagen-induced
phosphorylation of p38 MAPK. Lane 1, unstimulated platelets; Lane 2, collagen (10 μg/mL); Lane 3, collagen (10 μg/mL) + WIB-801CE
(200 mg/kg-BW); Lane 4, collagen (10 μg/mL) +WIB-801CE (400 mg/kg-BW). b Ex vivo effects of WIB-801CE on ADP-induced phosphorylation of p38 MAPK.
Lane 1, unstimulated platelets; Lane 2, ADP (5 μM); Lane 3, ADP (5 μM) +WIB-801CE (200 mg/kg-BW); Lane 4, ADP (5 μM) +WIB-801CE (400 mg/kg-BW).
c Ex vivo effects of WIB-801CE on collagen-induced phosphorylation of ERK2. Lane 1, unstimulated platelets; Lane 2, collagen (10 μg/mL); Lane 3, collagen
(10 μg/mL) + WIB-801CE (200 mg/kg-BW); Lane 4, collagen (10 μg/mL) + WIB-801CE (400 mg/kg-BW). d Ex vivo effects of WIB-801CE on ADP-
induced phosphorylation of ERK2. Lane 1, unstimulated platelets; Lane 2, ADP (5 μM); Lane 3, ADP (5 μM) + WIB-801CE (200 mg/kg-BW); Lane
4, ADP (5 μM) + WIB-801CE (400 mg/kg-BW). Western blotting was performed as described in “Methods” section. The data are expressed as the
mean ± standard deviation (n = 4). *p < 0.05 versus the each agonist-stimulated platelets. 1) Δ (%) = [(agonist + WIB-801CE 200 mg/kg-BW) –
agonist]/agonist × 100
Table 2 Ex vivo effects of WIB-801CE-administration on blood
coagulation
Animal group Dose (mg/kg-BW) PT (s) APTT (s) N
Normal N.D. 13.2 ± 2.3 26.2 ± 4.1 8
WIB-801CE 200 17.7 ± 4.9NS 26.3 ± 3.9NS 8
400 16.8 ± 3.2NS 26.0 ± 3.9NS 8
Warfarin 1 ∞ ∞ 6
The results were expressed as the mean ± standard deviation (n = 8 or 6). ∞,
no coagulation; NS not significant versus normal; N.D normal diet, N number
of tested rats; BW body weight, PT prothrombin time, APTT activated partial
thromboplastin time s, second
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(Fig. 6b). Cordycepin (56, 112 μM) corresponding to dose
(200, 400 μg/mL) of WIB-801CE attenuated thrombin-
induced fibrin clot retraction in a dose dependent manner
(Fig. 6a and b). Cordycepin (56 μM) corresponding to
200 μg/mL of WIB-801CE inhibited thrombin-induced
fibrin clot retraction (14.4 ± 5.1%) up to 59.1% (Fig. 6b).
In vitro and ex vivo effects of WIB-801CE on NO
production
It is well known that monocytes/macrophages and neutro-
phils produce various inflammatory mediators (i.e. NO,
Table 3 In vivo effects of WIB-801CE on tail bleeding time
Animal group Dose (mg/kg-BW) Tail bleeding time (s) Δ (%) N
Control Saline 125.3 ± 17.0 0 8
WIB-801CE 200 264.8 ± 79.0* 111.3 8
400 360.3 ± 83.8** 187.5 8
Aspirin 100 1,800.0 ± 0.0** 1,336.5 5
The results were expressed as the mean ± standard deviation (n= 8 or 5). *p< 0.05
compared with control, **p < 0.001 compared with control. N number of
tested mice, BW body weight, s, second Δ (%) = [(WIB-801CE or aspirin) control]/
control × 100
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generate atherothrombosis [52, 53]. In recent, it is also re-
ported that neutrophil-produced NO activates platelet in
chronic renal failure [54]. Accordingly, we investigated
whether WIB-801CE inhibits in vitro NO production in
RAW264.7 macrophage cells. As shown in Fig. 7a, lipo-
polysaccharide (LPS), an activator of macrophages, po-
tently produced NO as compared with that of normal.
However, WIB-801CE dose (15 to 50 μg/mL)-dependently
attenuated LPS-elevated NO production (Fig. 7a). iNOS
inhibitor AG potently inhibited NO production (Fig. 7a).
The ex vivo NO levels in plasma from PRP of control
(Fig. 7b, lane 2, 5) and WIB-801CE (200, 400 mg/kg-BW)
stimulated with collagen (Fig. 7b, lane 3, 4) and ADP
(Fig. 7b, lane 6, 7) were not changed as compared with
that (Fig. 7b, lane 1) in plasma from control rat, in the ab-
sence of ADP, collagen and WIB-801CE. These mean that
WIB-801CE (200, 400 mg/kg-BW) did not at least activate
inflammatory iNOS in leukocytes (i.e. monocyte, macro-
phage, neutrophil) in vivo. Otherwise, the ex vivo NO
levels would be increased in plasma from WIB-801CE
(200, 400 mg/kg-BW) stimulated with collagen and ADP.
In vitro effects of WIB-801CE on free radical scavenging
activity
Reactive oxygen species (ROS) activate platelets and
thrombogenesis [55–57]. In this study, we investigated
whether WIB-801CE has an antioxidant effect scaven-
ging ROS, which was evaluated as scavenging activity of
free radical in DPPH, a stable free-radical molecules
[25]. AC, a positive control, potently reduced the ab-
sorbance of DPPH. This means that AC has antioxidant
effect by scavenging free radical in DPPH [25]. WIB-
801CE also attenuated the absorbance of DPPH in aTable 4 In vivo effects of WIB-801CE on acute pulmonary thromboe





Protection (%) = (① - ②)/① × 100, Mortality (%) =②/① × 100. No., number of testeddose dependent manner (Fig. 7c). This result is indicated
that WIB-801CE has antioxidant effect by scavenging
free radical in DPPH like AC.
Ex vivo effects of cordycepin on platelet aggregation
As shown in Table 5, When PRP (108/mL) from control,
was activated with ADP (10 μM), the aggregation rate
was increased up to 75.7 ± 0.6%. But ADP-induced plate-
let aggregation significantly decreased by cordycepin (5,
10 mg/kg-BW) (Table 5). The inhibitory degree by
5 mg/kg-BW was 31.7%. This is higher than that (10.9%)
by WIB-801CE (200 mg/kg-BW) (Fig. 2b).
Discussion
WIB-801CE and its component cordycepin did not
affect the cytotoxicity (determined as LDH leakage) and
platelet activation (determined as platelet aggregation) to
resting human platelets in vitro. These mean that there
is no problem to evaluate the antiplatelet effects of
WIB-801CE ex vivo. It is well established that various
agonists (i.e. collagen, ADP, thrombin)-produced TXA2
generates circulatory disorder such as thrombosis, ath-
erosclerosis, and myocardial infarction by stimulating
platelet aggregation, vasoconstriction, and bronchocon-
striction [5, 58, 59]. Therefore, it is essential to inhibit
platelet aggregation and TXA2 production to prevent
circulatory disorder in blood vessel. WIB-801CE attenu-
ated ex vivo collagen- and ADP-induced platelet aggre-
gation and TXA2 production.
These results were connected to the ex vivo inhibition
of AA release and TXAS activity by WIB-801CE in col-
lagen- and ADP-activated platelets. WIB-801CE did not
also inhibit ex vivo collagen- and ADP-induced PLCβ3
(Ser537, Ser1105), PLCγ2 (Tyr
1217) phosphorylation. These
mean that WIB-801CE would produce DG from phos-
phatidylinositol 4,5-bisphosphate in collagen- and ADP-
activated platelets. DG is known to hydrolyze by p38
MAPK-activated DG-lipase to release AA [45]. If so, it is
considered that WIB-801CE may attenuate AA release
by inhibiting p38 MAPK/DG-lipase pathway [45] without
affecting inhibition of cPLA2 and PLCβ3 [9, 10, 42, 43].
Because agonist-produced TXA2 enforces thrombus
formation as a positive promoter [5, 58, 59], a com-
pound or substance that inhibits the activity of COX-1
or TXAS, the production of TXA2 or the action ofmbolism





mice; BW, body weight
ab
Fig. 6 In vitro effects of WIB-801CE and cordycepin on fibrin clot retraction. a In vitro effects of WIB-801CE and cordycepin on thrombin-induced fibrin
clot. b In vitro effects of WIB-801CE and cordycepin on thrombin-retracted clot retraction (%). Quantification of fibrin clot retraction was performed as
described in “Methods” section. The data are expressed as the mean ± standard deviation (n = 4). *p < 0.05 versus the thrombin-stimulated platelets. 1)
Δ (%) = [(agonist +WIB-801CE 200 μg/mL) - agonist]/agonist × 100, 2) Δ (%) = [(agonist + cordycepin 56 μM)- agonist]/agonist × 100
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ies have been performed to discover therapeutic agents
that can counteract the effects of TXA2. Various phyto-
chemicals (i.e. epigallocatechin-3-gallate, caffeic acid,
chlorogenic acid, caffedymine, sanguinarine) are known
to inhibit COX-1 rather than TXAS to suppress the
TXA2 production in vitro or ex vivo [60–65]. However,
WIB-801CE inhibited the activity of TXAS rather than
COX-1 ex vivo, which reflects that WIB-801CE inhibits
the TXA2 production pathway from PGH2 rather than
prostaglandin G2 production pathway from AA. In this
study, we showed that WIB-801CE may involve in
down-regulation of both p38 MAPK phosphorylation tovanish the AA supply from DG and TXAS activity to
block the TXA2 production from PGH2 ex vivo. There-
fore, it is apparent that WIB-801CE can be beneficially
used to prevent the TXA2-mediated thrombus formation
in vivo.
It is well known that agonist-released serotonin stimu-
lates irreversibly platelet aggregation, and subsequently
causes the thrombosis as well as TXA2 [66–68]. WIB-
801CE inhibited collagen- and ADP-induced serotonin
release ex vivo, which reflects that WIB-801CE can in-
hibit the irreversible platelet aggregation in vivo. WIB-
801CE potently inhibited ex vivo the phosphorylation of
p38 MAPK and ERK2 (42 kDa), but not Ca2+-dependent
ab
c
Fig. 7 (See legend on next page.)
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Fig. 7 Effects of WIB-801CE on NO production, and antioxidation activity. a In vitro effects of WIB-801CE on LPS-induced NO production.
b Ex vivo effects of WIB-801CE on collagen- and ADP-induced NO production. c In vitro effects of WIB-801CE on antioxidation activity.
Measurements were carried out as described in “Methods” section. The data are expressed as the mean ± standard deviation (n= 4). **p< 0.001
versus LPS-stimulated RAW264.7 cells. ††p< 0.001 versus the DPPH. NS, not significant versus the each agonist-stimulated platelets.1) Δ (%) = [(DPPH +
WIB-801CE 200 μg/mL) - DPPH]/DPPH × 100
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shown) that involves in serotonin release [14, 69–72] in
collagen- and ADP-activated platelets. These results are
allowed to consider that WIB-801CE seems to attenuate
ex vivo serotonin release by inhibiting the phosphoryl-
ation of p38 MAPK and ERK2 rather than MLC in colla-
gen- and ADP-activated platelets. This is similar to the
reports that some phytochemicals (i.e. caffeic acid phe-
nethyl ester, ginsenoside Rp1) inhibit collagen- and
ADP-induced ATP release by phosphorylating p38 MAPK
and ERK2 [39, 73].
In recent, we found that CE-WIB801C, n-butanol ex-
tracts from Cordyceps militalis, and cordycepin purified
from CE-WIB801C has in vitro antiplatelet effect by inhi-
biting fibrinogen binding to glycoprotein IIb/IIIa via stimu-
lation of cAMP-dependent phosphorylation of vasodilator-
stimulated phosphoprotein (Ser157), and inhibition of
phosphatidylinositol-3 kinase/Akt phosphorylation [74].
Antiplatelet effect of CE-WIB801C was involved in inhib-
ition of collagen-induced serotonin release. Accordingly, we
confirmed that the extracts from Cordyceps militaris have
antiplatelet effect in vitro and in vivo.
The formation of fibrin clot by intrinsic and extrinsic
blood coagulation factors together with platelet aggrega-
tion at injured blood vessels is another cause of thrombo-
genesis. WIB-801CE did not significantly prolong PT and
APTT as compared with that by normal ex vivo. This re-
flects that WIB-801CE has no anticoagulant characteris-
tics. WIB-801CE, however, weakly prolonged average PT
as compared with that by normal. The prolongation of PT
is associated with the reduction of coagulation factor VII
production by inhibition of NADPH-vitamin K reductase
[75]. The dose (1 mg/kg-BW) of warfarin, an inhibitor of
NADPH-vitamin K reductase, that unlimitedly prologned
PT is corresponded to high dose (60 mg/day) in case of






Control + ADP (10 μM) 75.7 ± 0.6 -
Cordycepin (5 mg/kg-BW) + ADP (10 μM) 51.7 ± 0.6** 31.7
Cordycepin (10 mg/kg-BW) + ADP (10 μM) 47.3 ± 2.5** 37.4
The data are given as the mean ± standard deviation (n = 3). **p < 0.001
compared with control. Inhibition (%) = [(cordycepin + ADP) – control]/
control × 100 (%)international normalized dose (5 mg/day) of warfarin [76].
In this study, because it is unknown whether the weak ex-
tension of average PT by WIB-801CE is clinically safety or
risk, it is necessary to investigate PT using international
normalized dose (5 mg/day) of warfarin, then the safety of
WIB-801CE in the weak extension of PT should be evalu-
ated in the future.
In addition, WIB-801CE without significantly affecting
the prolongation of blood coagulation time may not influ-
ence on inhibition of fibrin production. If so, because the fi-
brin is retracted by the interaction with platelet aggregation
[77], anybody may apprehend that the thrombus could be
generated by WIB-801CE in vivo. But it is considered that
its fear can be excluded because WIB-801CE inhibited both
thrombogenic TXA2 production and serotonin release
ex vivo, and thrombin-induced fibrin clot retraction
in vitro. These results mean that WIB-801CE can strongly
inhibit the fibrin clot retraction by down-regulating platelet
activation without significantly affecting the blood coagula-
tion. This is also evidenced as the effect that WIB-801CE
inhibited collagen plus epinephrine-induced acute pulmon-
ary thromboembolism in vivo, which is a marker of platelet
aggregation-generated thrombogenesis. At the present
study, however, it is unknown whether cordycepin in WIB-
801CE contributed to the inhibition of acute pulmonary
thromboembolism. These should be studied in the future.
As well as anticoagulants, antiplatelet drugs (i.e. aspirin,
clopidogrel) also cause bleeding, and surprisingly may
generate blood loss [21]. It is known that 20-40 mg/day of
aspirin is clinically used in human to protect thrombotic
disease [78]. The dose (100 mg/kg-BW) of aspirin, a posi-
tive control, seriously prolonged tail bleeding time of mice
as compared with that by control. This aspirin dose
(100 mg/kg-BW) is corresponded to high dose (6,000 mg/
day) in case of giving to human (60 kg), which is more
300-150 fold than clinical dose (20-40 mg/day) of aspirin
and impossible to compare with WIB-801CE in tail bleed-
ing time of mice. At the present study, because it is un-
known whether the significant extension of tail bleeding
time by WIB-801CE is clinically safety or risk, it is neces-
sary to investigate tail bleeding time using the clinical dose
(20-40 mg/day) of aspirin as positive control, then the
safety of WIB-801CE-prolonged tail bleeding time should
be evaluated in the future.
Leukocyte-produced ROS oxidizes low density lipo-
protein (LDL) in blood, then oxidized LDL (ox-LDL) is
incorporated into macrophage to generate foam cell
Kwon et al. BMC Complementary and Alternative Medicine  (2016) 16:508 Page 17 of 19which damages vascular wall by inducing inflammation.
Because platelet aggregation is caused at injured place of
vascular wall, the inflammation by leukocyte-produced
ROS and NO is the cause of thrombus formation. This
means that the counteraction of agonists-induced platelet
aggregation and leukocyte-induced inflammation might
be contributed to the inhibition of thrombosis. WIB-
801CE had ex vivo inhibitory effects on the release of
serotonin that stimulates the uptake of ox-LDL into
macrophage [79]. In addition, WIB-801CE inhibited NO
production and elevated scavenging activity of free radical
in DPPH in vitro. Therefore, it is anticipated that WIB-
801CE would not activate inflammatory leukocytes in vivo
as evidenced that WIB-801CE dose not affect ex vivo NO
production. These results suggest that WIB-801CE might
have antithrombotic effects by inhibiting inflammation via
antioxidative action.
Because we could not identify cordycepin or its metabo-
lites in PRP from WIB-801CE (200, 400 mg/kg-BW) rats,
in the present study, we could not explain whether cordyce-
pin in WIB-801CE was absorbed through intestine and
subsequently involved in inhibition of platelet aggregation.
This study should be performed in the future. Considering
antiplatelet effects observed by blood collection of 2 h after
final administration of WIB-801CE and 14 days after ad-
ministration of cordycepin, although cordycepin is metabo-
lized to an inactive 3'-deoxyhypoxanthinosine by adenosine
deaminase in rat blood [80–82], it could be thought that
unknown substances in WIB-801CE or cordycepin-derived
unknown substance might involve in inhibition of platelet
aggregation in an acute or chronic manner.
WIB-801CE (200, 400 mg/kg-BW)-dose independently
exerted its inhibitory effects on platelet aggregation,
TXA2 production, AA release, TXAS activity, serotonin
release, p38 MAPK phosphorylation and ERK2 phosphor-
ylation in ADP-activated platelets. Considering the in-
hibition of ADP-induced platelet aggregation is a
potential target to develop antithrombotic agent having
antiplatelet characteristics [36. 37], it is thought that
high dose of WIB-801CE (400 mg/kg-BW) might exert
undesirable effect on platelets in vivo.
Conclusion
Cordycepin-enriched WIB-801CE from Cordyceps militaris
vanished ex vivo thrombogenic molecules (TXA2, sero-
tonin), and their associated signaling molecules (AA, TXAS,
p38 MAPK, ERK2) in platelet aggregation. Furthermore, WIB-
801CE inhibited in vivo acute pulmonary thromboembol-
ism, an index of thrombotic formation, without having cyto-
toxicity and risk of serious bleeding, but with antioxidant
and antiinflammatory activity. Therefore, we suggest that
WIB-801CE may be a beneficial and effective substance to
treat or protect thrombosis, atherosclerosis, and myocardial
infarction via inhibition of platelet activation in vivo.Abbreviations
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